← ANALYST RATINGS · TIPRANKS
Humacyte (HUMA): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy2 Hold0 Sell
Ratings of 4 analysts in the last 3 months · top analysts only12-month forecast
Based on 4 price targets given in the last 3 months, the average target is $1.69, the highest $4.00, the lowest $0.50. The average is +293.4% from the last price of $0.43.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $0.35 → $0.44+26.5% | Hold | +2.3% | Reiterated | 16.10.26on TipRanks 12:05 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $0.35 → $0.43+23.3% | Hold | −0.2% | Reiterated | 16.10.26on TipRanks 12:05 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $0.35 → $0.43+23.3% | Hold | −0.2% | Reiterated | 16.10.26on TipRanks 12:05 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $0.36 → $0.45+25.4% | Hold | +5.8% | Reiterated | 16.10.26on TipRanks 12:05 | — | |
| Swayampakula Ramakanth★★★★★★★★★★#445 · hits 47% · avg +21.2% | H.C. Wainwright | $4.00 | Buy | +832.4% | Reiterated | 16.10.26on TipRanks 06:35 | −1.2% | ↗ |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $0.35 → $0.43+22.8% | Hold | −0.7% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $0.35 → $0.43+22.6% | Hold | −0.2% | Reiterated | 16.10.26on TipRanks 02:05 | — | |
| Matt Miksic★★★★★★★★★★#2645 · hits 55% · avg +3.9% | Barclays | $0.50 | Hold | +16.6% | Initiated | 07.10.26on TipRanks 03:55 | −1.0%next day −4.9% · 5 days −24.0% | ↗ |
| Josh Jennings★★★★★★★★★★#3537 · hits 46% · avg +3.0% | TD Cowen | $1.25 | Buy | +191.4% | Reiterated | 19.08.26on TipRanks 15:00 | +26.1%next day −6.4% · 5 days −6.8% | ↗ |
| Allison Bratzel★★★★★★★★★★#171 · hits 64% · avg +41.9% | Piper Sandler | $1.00 | Hold | +133.1% | Reiterated | 17.08.26on TipRanks 07:38 | −6.8%next day +4.4% · 5 days +19.4% | ↗ |
| Ryan Zimmerman★★★★★★★★★★#3375 · hits 46% · avg +3.3% | BTIG | $2.00 | Buy | +366.2% | Reiterated | 28.07.26on TipRanks Jul 29 06:42 | −6.8%next day +0.6% · 5 days +8.9% | ↗ |
| Bruce Jackson★★★★★★★★★★#12272 · hits 38% · avg −9.8% | Benchmark Co. | $1.00 → $2.00+100.0% | Buy | +366.2% | Reiterated | 01.06.26on TipRanks 07:30 | +11.3%next day −4.3% · 5 days −2.3% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Humacyte
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 07.10.26: target $1.75 at a price of $0.48 (+266.1%); now: $1.75 at $0.43 (+307.9%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 6 | 3 | 4 | 4 | 5 |
| Buy | 3 | 5 | 4 | 2 | 0 | 0 |
| Hold | 2 | 2 | 2 | 2 | 1 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 06.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.10 (from $-0.12 to $-0.07). Last quarter: $-0.16.
Sales
Next quarter’s sales estimate — $1M (from $0M to $1M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Humacyte
- CEO: Laura E. Niklason
- Employees: 184
- 2525 East North Carolina Highway 54, Durham, NC, 27713, US
- www.humacyte.com
Humacyte, Inc. focuses on developing and manufacturing readily available, implantable human tissues engineered in a laboratory setting. These bioengineered tissues are designed to treat a wide array of diseases and conditions across various anatomical locations and therapeutic fields. The company employs its distinct scientific and proprietary technology platform to produce human acellular vessels (HAVs). These investigational HAVs are specifically crafted for universal compatibility, enabling easy implantation into any patient without inducing an immune rejection or an adverse foreign body response. Humacyte is currently building a pipeline of HAVs targeting the substantial market for vascular repair, reconstruction, and replacement. This includes applications such as treating vascular trauma, providing arteriovenous access for hemodialysis, addressing peripheral arterial disease, and facilitating coronary artery bypass grafting. Furthermore, the company is exploring the use of its HAVs for pediatric heart surgeries and for cellular therapeutic delivery, including the transplantation of pancreatic islet cells to manage Type 1 diabetes. Founded in 2004, Humacyte maintains its headquarters in Durham, North Carolina.
Data from the stock’s TipRanks forecast page, read 63 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗